Japan Unit Of AstraZeneca Begins Second-Phase Trials For Lupus Drug
This article was originally published in PharmAsia News
Executive SummaryThe Japanese unit of U.K.-based AstraZeneca says it has begun Phase II trials of its MEDI-545 (sifalimumab) drug for treating lupus. The treatment being tested by AstraZeneca KK relies on supplying an antibody for interferon alpha considered to be the cause of lupus in high concentrations. Another AstraZeneca subsidiary, U.S.-based Medimmune, created the drug in 2004 and is developing it through its subsidiaries in Japan, Europe and the United States. (Click here for more - a subscription may be required
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.